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Abstract
Nicotine stimulation of a7 nicotinic acetylcholine receptor (a7 nAChR) powerfully inhibits pro-inflammatory cytokine
production in lipopolysaccharide (LPS)-stimulated macrophages and in experimental models of endotoxemia. A signaling
pathway downstream from the a7 nAChRs, which involves the collaboration of JAK2/STAT3 and NF-kB to interfere with
signaling by Toll-like receptors (TLRs), has been implicated in this anti-inflammatory effect of nicotine. Here, we identifiy an
alternative mechanism involving interleukin-1 receptor-associated kinase M (IRAK-M), a negative regulator of innate TLR-
mediated immune responses. Our data show that nicotine up-regulates IRAK-M expression at the mRNA and protein level in
human macrophages, and that this effect is secondary to a7 nAChR activation. By using selective inhibitors of different
signaling molecules downstream from the receptor, we provide evidence that activation of STAT3, via either JAK2 and/or
PI3K, through a single (JAK2/PI3K/STAT3) or two convergent cascades (JAK2/STAT3 and PI3K/STAT3), is necessary for
nicotine-induced IRAK-M expression. Moreover, down-regulation of this expression by small interfering RNAs specific to the
IRAK-M gene significantly reverses the anti-inflammatory effect of nicotine on LPS-induced TNF-a production. Interestingly,
macrophages pre-exposed to nicotine exhibit higher IRAK-M levels and reduced TNF-a response to an additional LPS
challenge, a behavior reminiscent of the ‘endotoxin tolerant’ phenotype identified in monocytes either pre-exposed to LPS
or from immunocompromised septic patients. Since nicotine is a major component of tobacco smoke and increased IRAK-M
expression has been considered one of the molecular determinants for the induction of the tolerant phenotype, our
findings showing IRAK-M overexpression could partially explain the known influence of smoking on the onset and
progression of inflammatory and infectious diseases.
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Introduction
Cigarette smoking stronggly influences the onset and clinical
course of various pathologies through a complex set of actions
affecting the body’s defense mechanisms that range from pro-
inflammatory to immune-suppressive [1–4]. The specific mecha-
nisms by which the individual components of cigarrette smoke
affect the host’s inflammatory response are incompletely under-
stood, so their study represents a first step toward establishing the
most appropiate therapeutic strategies for the management of
diseases in patients who are smokers.
Nicotine, a major component of tobacco smoke, has been
shown to strongly modify the inflammatory response both in vitro
and in vivo [5–8]. Its anti-inflammatory action, like that of the
endogenous neurotransmitter ACh, is due to its binding to and
activation of a7 nicotinic acetylcholine receptors (a7 nAChRs) on
resident macrophages under the control of the ‘cholinergic anti-
inflammatory pathway’ (CAP) [5,6,9,10]. This anti-inflammatory
pathway, first identified by the Tracey group, constitutes the
efferent arm of a vagal nerve circuit directly linked to the immune
system. The physiological activation of CAP is critical to ensure
the appropriate magnitude of the inflammatory response to an
infection or injury since it culminates in T cell release of ACh and
the interaction of the neurotransmitter with a7 nAChRs on
resident macrophages in the spleen, thereby inhibiting pro-
inflammatory cytokine production by these macrophages [11,12].
The discovery that CAP is a major modulator of immune cell
function in a wide variety of inflammatory disease states [13,14]
has prompted the study of the downstream signaling from the a7
nAChRs involved in the ACh or nicotine anti-inflammatory effect.
Available data reveal the involvement of signaling pathways that,
directly or indirectly, lead to activation of the signal transducer
and activator of transcription 3 (STAT3) via Janus-kinase 2 (JAK2)
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and/or to inhibition of the nuclear translocation of NF-kB, the
first and last being central transcription factors for innate and
adaptive immunity [7,15,16,17]. Determining how STAT3 is
involved in the anti-inflammatory effect mediated by a7 nAChRs
is another challenge, although we know that activated STAT3
may act either directly or indirectly, depending on the type of
activating stimulus. In the first case, phosphorylated STAT3 forms
dimers that translocate into the nucleus, where they act as a
negative regulator of proinflammatory cytokine expression
[16,17]. In the second case, STAT3 may converge and interfere
with NF-kB activation in such a way that, upon becoming
activated, a NF-kB p65 homodimer recruits and associates with
STAT3 [18,19].
Toll-like receptors (TLRs) are an essential receptor family for
initiating activation of the innate immune response to various
pathogens. To do this, these receptors recognize a variety of
pathogen-associated molecular patterns (PAMPs), such as lipo-
polysaccharide (LPS) (endotoxin), which, in turn, activates TLR4
and triggers intracellular signaling pathways that lead to the
production of pro-inflammatory cytokines [20,21]. However,
excessive immune response to TLR stimulation is detrimental to
the host, even lethal, so this process must be tightly regulated by
protective mechanisms that counteract excessive immune activity.
An example of such mechanisms is ‘endotoxin tolerance’, a
phenomenon reported in monocytes/macrophages that have
either been pre-exposed to LPS or come from immunocompro-
mised septic patients; these cells enter a transient refractory state of
hyporesponsiveness to subsequent LPS challenge and are unable
to produce pro-inflammatory cytokines at levels comparable to
those seen during the first LPS exposure or before sepsis [22–24].
Other examples of protective mechanisms include a large number
of signaling molecules whose expression can negatively regulate
TLR signaling, and they thus play a pivotal role in controlling
innate responses in immune cells [19,22,25–29]. These molecules
include STAT3, suppressors of cytokine signaling 1 and 3 (SOCS-
1, SOCS-3), phosphatidylinositol 3-kinase/threonine protein
kinase B (PI3K/Akt), myeloid differentiation primary response
gene 88 (MyD88), and interleukin-1 receptor-associated kinase-M
(IRAK-M). Interestingly, some of these negative regulators of TLR
signaling (STAT3, SOCS-3, PI3K and MyD88s) have also been
implicated in the anti-inflammatory effect mediated by a7
nAChRs in immune cells [16,30–32]. However, the participation
of others, like IRAK-M, is yet to be evaluated.
IRAK-M, first characterized in humans [33], is a member of the
IRAK family that, unlike other active members of this family
(IRAK-1 and IRAK-4), lacks kinase activity. This inactive kinase
(or pseudokinase) appears to be exclusively expressed in mono-
cytes/macrophages of different species [33,34], and its expression
can be induced not only by TLR activation (e.g. with the TLR4
ligand, LPS), but also in response to endogenous or exogenous
soluble factors (adiponectin or prostaglandin E2), as well as to cell
surface or intracellular signaling molecules (such as PI3K) (see Ref.
[29] and references therein). Once IRAK-M expression is induced
by TLR ligands, it may act as a negative regulator of the TLR
signaling pathway by preventing the dissociation of the active
IRAKs (IRAK-1 and IRAK-4) from MyD88 and the subsequent
formation of a complex with TNF receptor-associated factor 6
(TRAF6), thereby inhibiting downstream inflammatory signals
and suppressing production of the pro-inflammatory mediators
controlled by this signaling pathway [22,24,35]. Accordingly,
IRAK-M-deficient macrophages produce higher levels of pro-
inflammatory cytokines upon TLR/IL-1R stimulation. Based on
the above findings, IRAK-M levels have been negatively
associated with the magnitude of the inflammatory response in
human sepsis, supporting a prominent role for IRAK-M in the
regulation of immune homeostasis in infectious and non-infectious
human diseases [23,29,36,37]. Furthermore, up-regulation of
IRAK-M and other negative TLR4 regulators, along with
impaired activation of IRAK4, p38, and NF-kB, have been
recognized as molecular determinants for the induction of
‘endotoxin tolerance’ in monocytes, which may have important
pathophysiological implications in vivo [23,36,38].
We hypothesized that IRAK-M may contribute to the well-
known anti-inflammatory effect of nicotine acting on a7 nAChRs
in human macrophages on the basis of the above evidences, which
are summarized as follows: 1) the overlapping expression of
IRAK-M and a7 nAChRs in the same cell types (macrophages); 2)
the decisive role of IRAK-M in negatively regulating the
inflammation mediated by TLR signaling; and 3) the involvement
of other negative regulators of TLR signaling in the anti-
inflammatory effect mediated by a7 nAChRs in macrophages.
The present study tested this hypothesis by analyzing the possible
connection between nicotine and IRAK-M via a7 nAChRs in
human macrophages and also by studying whether this molecular
mechanism could be behind the anti-inflammatory and immuno-
suppresant effects of nicotine.
Materials and Methods
Reagents
Unless otherwise indicated, all products were purchased from
SIGMA (Madrid, Spain). DMEM and RPMI media were from
Gibco (Invitrogen, UK). PNU120596 and all of the inhibitors used
in this study were purchased from Tocris Bioscience (Bristol, UK).
Cell Isolation and Culture
Human PBMC were isolated as described elsewhere [23,39–41]
from blood buffy coat cells from healthy individual donors
provided anonymously by the Blood Transfusion Center of the
Comunidad de Madrid. Data from these blood samples were
analyzed anonymously. Cells were collected, washed, resuspended
in complete RPMI 1640 medium (GIBCO, Invitrogen) without
serum and seeded onto 60 mm Petri dishes (26107 cells per dish),
onto coverslips in 24-well culture plates (106 cells per well), or onto
6-well culture plates (107 cells per well). After 2 hours, the adherent
monocyte-enriched cell population (about 10% of total PBMC)
was washed with the medium and monocytes allowed to
diferentiate into macrophages for 3, 8 or 12 days in the presence
of M-CSF (2 ng.ml21) and complete culture medium with 5%
human serum in a 5% CO2 environment at 37uC following the
protocol described by the Kevin J Tracey group [5,6,9]. Unless
otherwise noted, most experimental protocols were done with
human macrophages (MØ) differentiated for 10–12 days from
monocytes and confirmed by CD14 and CD89 positive cell
surface expression. Macrophages from the RAW 264.7 cell line
(immortalized mouse leukemic monocyte macrophage cells, from
American Type Culture Collection ATCC, Manassas, VA, USA)
were maintained in RPMI 1640 medium supplemented with 10%
FBS in a humidified incubator in a 5% CO2 environment at 37uC.
Cells were subcultured before confluence, seeded on 60 mm Petri
dishes, and then allowed to grow to 80% confluence on the dish
before being subjected to different treatments.
Protein Extraction and Western Blot Analysis
After being subjected to different treatments, MØ or RAW
264.7 cells were placed on ice and washed with cold PBS. Cells
were lysed with lysis buffer [50 mM Tris-HCl, 150 mM NaCl,
1 mM EDTA, 1% w/w NP-40; pH 8.0] containing a complete
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protease inhibitor cocktail (Sigma-Aldrich, USA) and phosphatase
inhibitors (5 mM sodium fluoride, 1 mM sodium orthovanadate
and 5 mM beta-glycerophosphate) in the case of phosphorylation
assays. Protein concentration was determined by a BCA assay kit
(Pierce BCA Protein Assay kit, Thermo Fisher Scientific, USA),
and gels loaded with equal amounts of protein per lane (30–40 mg
protein/lane). Next, proteins were resolved by 10% SDS/PAGE
gel electrophoresis, transferred to a PVDF membrane (Millipore),
and analyzed by Western blot using the appropriate antibodies.
The primary antibodies [rabbit anti-IRAK-M polyclonal antibody
(Millipore) or goat anti-b-actin monoclonal antibody (Santa Cruz
Biotechnology, CA, USA)] were diluted 1:1000 in TTBS buffer,
and incubated 1 hour at room temperature. For phosphorylation
assays, blots were incubated overnight at 4uC with the following
anti-phospho and non-phospho primary antibodies (dilution
1:1000) from Cell Signaling (Beverly, MA, USA), unless otherwise
indicated: rabbit monoclonal anti-pERK1/2 (Thr202/Tyr204);
rabbit polyclonal anti-ERK (Millipore); rabbit polyclonal anti-
pJAK2 (Tyr1007/1008); rabbit polyclonal anti-JAK2; rabbit
monoclonal anti-pSTAT3 (Tyr705), rabbit polyclonal anti-
STAT3; rabbit monoclonal anti-pAkt (Ser473); and rabbit
polyclonal anti-Akt. Proteins were detected using the appropiate
secondary (HRP)-conjugated antibody (from Jackson Immuno
Research PA, USA, or Cell Signaling) and incubated for 1 hour at
room temperature at the dilution recommended by the manufac-
turer. The resulting bands were detected using ECL Plus reagents
(Amersham, GE Healthcare, UK) and quantified by densitometry
using Image J software (National Institutes of Health, USA).
Quantitative Real-Time PCR (qPCR) Analysis of Gene
Expression
The level of IRAK-M mRNA expression in MØ was assessed
by qPCR from reverse-transcribed total RNA previously isolated
from the cells with the RNeasy Mini kit (Qiagen, Hilden,
Germany) as described [39]. A SYBR green-based assay was used
for amplicon detection on the ABI Prism 7500 device. The
following primers were used: for IRAK-M, forward 5’-
TTTGAATGCAGCCAGTCTGA and reverse 5’-GCATTGCT-
TATGGAGCCAAT; for b-2-Microglobulin (B2M), used as an
internal control, forward 5’-TGCCTGCCGTGTGAACC-ATGT
and reverse 5’-TGCGGCATCTTCAAACCTCCATGA. Analy-
sis of the melting curves demonstrated that each pair of primers
amplified a single product. qPCR for IRAK-M mRNA was
performed in triplicate and later normalized to the expression of
B2M mRNA. Relative gene expression values were calculated by
the comparative 22DDCt method using Sequence Detection System
1.2 software (Applied Biosystems).
Flow Cytometry
Monocyte-enriched population seeded onto 60 mm Petri dishes
was washed with PBS and detached from the plate using 5 mM
EDTA/PBS solution. The cell suspension was centrifuged and the
resulting pellet incubated for 20 minutes at 4uC with a 2 mM
EDTA/0.5% FBS/PBS solution containing the mouse anti-
human CD89-FITC (AbD SEROTEC, Oxford, UK) and the
mouse anti-human CD14-APC (Miltenyi Biotec, Bergisch Glad-
beach, Germany). In another set of experiments, the pellet
obtained as above, but starting with cell suspensions of human
monocytes at various stages of differentiation to MØ (3, 8 and 12
days), were incubated for 20 minutes at 4uC with a 2 mM EDTA/
0.5% FBS/PBS solution containing a combined mixture of the
specific labelled toxin for the a7 nAChR, aBgtx-FITC
(3 mg. ml21, Sigma), and mouse anti-human CD14-APC. After
staining, cells were washed and resuspended in 2 mM EDTA/PBS
solution and processed on a BD FACSCanto II flow cytometer
equipped with BD FACSDiva software.
Confocal Microscopy Analysis of Receptor Expression
The native expression level of functional a7 nAChRs in MØ
was also analyzed by confocal microscopy using aBgtx-FITC.
Cells seeded on coverslips were incubated with the labeled toxin
(3 mg. ml21) as previously described [39]. After several rinses, MØ
were fixed, washed, mounted and visualized with the Leica TCS
SP2 Spectral confocal laser scanning microscope. All images were
captured with the Leica Confocal Software using the same
adjustments of laser intensity and photomultiplier sensitivity as
described elsewhere [39,42,43].
Gene Silencing by Transfection of Stealth RNA
Interference (siRNA)
Two different non-overlapping StealthTM RNAi duplexes
(siRNA-1 and siRNA-2) designed for silencing the human
IRAK-M gene (NM_007199.2) and the corresponding negative
StealthTM RNAi duplex control (siRNA control; Medium GC
Duplex) were purchased from Invitrogen (Life Technologies,
Paisley, UK). The IRAK-M siRNA-1 and IRAK-M siRNA-2
sequences were designed to target base pairs 1336–1360 (sense
strand, 5’-CGG AAU UUC UCU GCC AAG CUC UUC U-3’;
antisense strand, 5’-AGA AGA GCU UGG CAG AGA AAU
UCC G-39) and base pairs 1487–1511 (sense strand, 5’-CCU
UCA GGU GUC CUU CUC UAU U-3’; antisense strand, 5’-
AAU AGA CGA GAA GGA CAC CUG AAG G-3’) of the
IRAK-M gene. Before transfection, human PBMC were seeded in
6-well culture plates and the adherent monocyte-enriched
population allowed to diferentiate into MØ in complete RPMI
1640 medium (plus 5% v/v human serum and 2 ng.ml21 M-CSF)
as described before. Silencing of the IRAK-M gene was performed
according to the protocol previously described for human
macrophages [44]. Briefly, cells were incubated at 37uC for 6 h
with a transfection master mix containing fresh serum-free
OptiMEM medium (Invitrogen, Life Technologies), the siRNA-1
or siRNA-2 (or the negative siRNA control) at a final concentra-
tion of 1 nM in the well, and INTERFERin (Polyplus, Illkirch,
France). Then, the above master mix was replaced overnight by
serum-free RPMI 1640 medium. After this period, MØ were
exposed to various treatments specified in the Results section and
then the IRAK-M expression knock-down was analyzed in the
protein extract from the cell lysate using Western blot and the
TNF-a concentration in the cell supernatants using ELISA.
Tolerance Induction
A Monocyte-enriched population was cultured in 6-well culture
plates and allowed to diferentiate into MØ in complete RPMI
1640 medium. The cells were divided into four groups (5 wells/
group). Group 1 was maintained in culture medium alone
throughout the experiment (48 h). Group 2 was pre-incubated in
culture medium for 8 h, washed three times with fresh medium
and maintained in culture for 16 h, and then stimulated with LPS
for 24 h. Groups 3 and 4 were preincubated with LPS or nicotine
for 8 h respectively, washed as in group 2, and stimulated with
LPS for 24 h. Upon completion of the protocol, we proceeded to
perform Western blot to analyze IRAK-M expression in the cell
extract, and ran an ELISA analysis to detect TNF-a in cell
supernatants from all four groups.
Nicotinic Anti-Inflammatory Effects via IRAK-M
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Cytokine Detection by Elisa Analysis
At the end of the cell treatments, supernatants were harvested
and stored at 220uC. Levels of TNF-a in the culture supernatants
were determined using a commercial ELISA kit (Human TNF-a
ELISA Development Kit from PeproTech EC Ltd., London, UK)
according to the manufacturer’s instructions.
Statistical Analysis
All of the data are presented as mean values 6 SEM from at
least three independent experiments. One-way analysis of variance
(ANOVA) was used for multiple comparisons between the groups
followed by a specific post-hoc test (Bonferroni) to analyze the
differences. Student’s t-test was used when only 2 groups were
compared. A p#0.05 was considered statistically significant.
Results
Nicotine Induces IRAK-M expression in Human and
Mouse Macrophages
Nicotine attenuates LPS-induced pro-inflammatory cytokine
production in macrophages while IRAK-M is a negative regulator
of innate TLR/IL-1R-mediated immune responses in the same
cell type. To assess whether there is any relationship between
nicotine and this negative inflammation regulator, we used
immunoblotting and qPCR assays to measure the nicotine effect
on IRAK-M expression in human macrophages (MØ) differenti-
ated from monocytes. IRAK-M protein levels were significantly
higher in cells stimulated with nicotine (24 h) compared to non-
stimulated cells from the same culture (Figure 1A). In fact, nicotine
caused a ,3.5-fold increase in IRAK-M levels, an effect similar to
that obtained when incubating MØ with LPS for a similar period
of time (Figure 1A). To analyze whether the up-regulation of
IRAK-M elicited by nicotine was the result of increased gene
transcription, we performed qPCR experiments to determine the
time-course of IRAK-M mRNA levels in MØ stimulated with
nicotine for different periods (Figure 1B). Non-stimulated cells or
cells stimulated with LPS (100 ng.ml21, 6 h) from the same batch
were used as negative and positive controls, respectively. We
performed qPCR with total RNA isolated from MØ using B2M as
an internal control and the primers listed in the ‘‘Material and
Methods’’ section. Our results show that nicotine up-regulates
IRAK-M mRNA expression, with levels peaking at 6 h and then
declining to baseline levels at 24 h of incubation with the drug.
The threshold concentration of nicotine and its kinetic effect on
IRAK-M expression in MØ could be reproduced in macrophages
from a different species, the mouse RAW 264.7 cell line.
Figure 1C shows the Western blot analysis of results obtained in
each cell type incubated with varying concentrations of nicotine
applied for 24 h. In both types of macrophages, the nicotine effect
is seen at concentrations above 100 nM and then increases in
parallel to the concentration of the agonist. Figure 1D shows the
Western blot analysis for the time-course of the nicotine (1 mM, at
the indicated times) effect on IRAK-M expression in MØ and
RAW 264.7 cells. Results reveal that the effect begins to be
significant at 6 hours, reaches a maximum at 24 h and declines
thereafter. For this reason, a stimulation period of 24 h was
selected for subsequent experiments.
The a7 nAChR Subtype is involved in the Nicotine-
induction of IRAK-M Expression in MØ
FACS analysis of a representative culture sampling (n = 12) of
all the cultures used in this study (n = 56) reveals that most of the
adherent cells isolated from buffy coat blood from healthy
volunteers were CD14+ (92.462.1%) and CD89+ (93.262.4%)
cells (data not shown). This type of analysis performed on CD14+
cells labeled with aBgtx-FITC makes it possible to assess the
expression level of a7 nAChRs in monocytes at different stages of
their differentiation into macrophages (3, 8 and 12 days).
Figure 2A shows that receptor expression is easily detectable on
day 8 of differentiation and continues increasing until days 10–12.
Thus, all experiments for the present study were performed in MØ
differentiated for the longest time period. The expression of a7
nAChRs in MØ was also confirmed by confocal microscopy in
cells immunostained with aBgtx-FITC, as has been reported
previously in our laboratory [39]. Figure 2B shows a confocal
image obtained in a typical culture of MØ differentiated for 12
days and stained with the labeled toxin. Receptor labeling with
aBgtx-FITC is specific since it was abolished when macrophages
from the same batch were preincubated with unlabeled 1 mM
aBgtx (not shown) or with 500 mM nicotine (Figure 2C).
Figure 2D shows a transmitted light image of the cells in the
same field as Figure 2C, and Figure 2E of a different field from the
same culture at a higher magnification to visualize morphological
changes of the monocyte-derived macrophages with differentia-
tion.
Once the optimal differentiation period to obtain the peak a7
nAChR expression had been established in MØ, we studied
whether this receptor subtype was implicated or not in the nicotine
effect on IRAK-M in these cells. To this purpose we evaluated the
effect of aBgtx and PNU120596 on the nicotine effect; the former
is a specific and potent inhibitor of a7 nAChR while the latter is a
positive allosteric modulator of this receptor subtype. For these
experiments, cells were incubated with aBgtx (30 min) or
PNU120596 (10 min) before and during their nicotine incubation
(24 h). Figure 2F shows that aBgtx completely abolished the
nicotine effect on IRAK-M expression without affecting the LPS
effect on that expression (not shown). Conversely, PNU120596
produced a dose-dependent increase in the nicotine effect,
although the drug had no effect by itself, even at 30 mM, the
highest concentration assayed in these experiments (Figure 2G). It
should be noted that the concentration of nicotine used in the
PNU120596 experiment was lower (100 nM) than the one used in
previous experiments to make it easier to distinguish the
enhancing effect of the positive allosteric modulator on the a7
nAChR-mediated signal.
Signaling Pathways Connecting a7 nAChRs with IRAK-M
in MØ
In order to ascertain the possible signaling pathways involved in
the nicotine-mediated up-regulation of IRAK-M via a7 nAChRs
in MØ, we took advantage of the availability of selective inhibitors
of various kinases (PD98059 for MEK1; U0126 for ERK1/2;
SB203580 for p38MAPK; AG-490 for JAK2 and LY 294002 for
PI3K) and transcription factors (Tanshinone II-A for AP-1 and
STA-21 for STAT3) that have been recognized as signaling
molecules downstream from the a7 nAChRs in different cell types,
including macrophages and neurons [16,17,31,45–53]. In these
experiments, the effects of the above inhibitors on nicotine-
induced IRAK-M expression (Figure 3A–B) or on nicotine-
mediated phosphorylation of signaling molecules downstream
from the a7 nAChR (Figures 3C–E) were assessed in MØ by
Western blot. For IRAK-M expression analysis, the inhibitors
were preincubated 30 min before and during the nicotine stimulus
(1 mM, 24 h), at the concentrations indicated in the Figure. MØ
from the same buffy coat culture either non-stimulated with
nicotine or incubated with LPS (100 ng.ml21, 24 h) were used as
respective negative and positive controls for IRAK-M expression.
Nicotinic Anti-Inflammatory Effects via IRAK-M
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Immunoblotting revealed that, with the exception of the inhibition
of p38MAPK leading to a partial, yet significant, reduction in the
nicotine-dependent up-regulation of IRAK-M, the inhibition of
MEK, ERK1/2 or AP-1 left the nicotine effect untouched, even at
the highest concentration of the inhibitor used (Figure 3A).
Conversely, inhibition of JAK2, STAT3 or PI3K, caused a
greater-than-80% inhibition of the nicotine effect on protein
expression, even at the lowest inhibitor concentration used
(Figure 3B).
The finding that JAK2, STAT3 and PI3K contribute equally to
nicotine-induced IRAK-M overexpression (Figure 3B) suggests
that these three signaling molecules may be chained or converge in
a common signaling pathway leading to the induction of IRAK-
M. To test this hypothesis we focused our attention on those
signaling routes that, according to previous studies (for more
detail, see references in the corresponding section of Discussion),
provide connection for the above signaling molecules: activated
JAK2 can phosphorylate either STAT3 or PI3K/Akt and
activated PI3K can phosphorylate STAT3. Once we had
established the signaling pathways of interest, we used Western
blot to explore whether the specific blockade of the first signaling
molecule in each cascade affected the nicotine-mediated phos-
phorylation of signaling molecules downstream. The inhibitors
were preincubated 30 min before and during the nicotine stimulus
(1 mM, 30 or 60 min), at the concentrations indicated at the
bottom of Figure 3 (panels D–E). The results show that the
inhibition of JAK2 (AG-490) reduced the phosphorylation of both
STAT3 and PI3K/Akt induced by nicotine (panel D); similarly,
inhibition of PI3K (LY 294002) also interrupts the nicotine-
mediated phosphorylation of STAT3 (panel E). Moreover,
although we have found that 60 min of incubation with nicotine
activates ERK1/2 in MØ (Figure 3C), this route did not
contribute to the effect of nicotine on IRAK-M expression, as
can be inferred from the lack of effect on expression (Figure 3A) by
the selective inhibitor of the kinase (U0126).
Specific IRAK-M Gene Silencing Suppresses the Anti-
inflammatory Effect of Nicotine on TNF-a Production in
LPS-stimulated MØ
In order to test whether up-regulated IRAK-M gene expression
is involved in the anti-inflammatory effect of nicotine, we
proceeded to evaluate the nicotine effect on cytokine production
in MØ stimulated with LPS (100 ng.ml21; 18 h) after silencing
IRAK-M gene expression with two different non-overlapping
siRNA duplexes (siRNA-1 and siRNA-2). Nicotine pre-incubation
of cells was started 3 h before and continued during the LPS
stimulation. As illustrated in Figure 4A, a typical Western blot
from five independent experiments, the mean 6 SEM values of
IRAK-M expression dropped by 44.463.3% and 66.062.2% in
LPS-activated cells transfected with siRNA-1 or siRNA-2 respec-
tively, compared to non-transfected cells or cells transfected with
the negative siRNA control. Figure 4B shows, in parallel with the
above Western blots, the effect of nicotine on TNF-a production
in LPS-simulated MØ as a function of silencing of IRAK-M gene
expression. Results reveal that the anti-inflammatory effect of
nicotine on the TNF-a production in simulated MØ was
significantly reversed by cell transfection with siRNA-1 or
siRNA-2, but not with the negative siRNA control. As expected,
aBgtx, placed in the incubation medium 45 min before and during
the nicotine treatment, also produced a significant reversal of the
nicotine anti-inflammatory effect in LPS-simulated cells.
Pre-incubation of MØ with Nicotine Enhances IRAK-M
Expression and Inhibits TNF-a Production in Response to
LPS
Monocytes/macrophages previously exposed to LPS develop
‘endotoxin tolerance’, which makes the cells hypo-responsive to
subsequent LPS exposure. Up-regulation of IRAK-M has been
identified as one of the molecular determinants implicated in the
induction of this process. Since our study shows that nicotine
reproduces the effect of LPS on IRAK-M expression in MØ, we
wanted to investigate whether the cholinergic agonist can, like
LPS, induce a refractory state in the cells, leading to a reduced
inflammatory response to subsequent LPS challenge. The results
in Figure 5 indicate that this is the case; the figure also includes the
various experimental conditions tested (Figure 5A). By respectively
doing Western blot and ELISA assays in the MØ extract and
supernatants, we proceeded to simultaneously determine IRAK-M
expression and TNF-a levels in each experimental condition. This
experimental design was repeated with five different cultures. The
results show that MØ pre-exposed to either nicotine or LPS
present a significantly enhanced IRAK-M expression and
decreased TNF-a response to a subsequent stimulation with LPS
in comparison to cells that have not been pre-exposed to either
nicotine or LPS (Figure 5B–C).
Discussion
This study provides a novel mechanistic explanation for the
anti-inflammatory effect of nicotine downstream from a7 nAChRs
in human macrophages: IRAK-M gene expression is upregulated
by nicotine, and this has an anti-inflammatory effect. In addition,
our study also reveals that exposure to nicotine, as previously
described with LPS exposure, reprograms macrophages into a
refractory and hyporesponsive state toward additional TLR
stimulations that might compromise the normal immune response.
In our study, nicotine induces overexpression of IRAK-M
protein in MØ to levels similar to the response to LPS, which is
used as the reference stimulus for up-regulation of this pseudo-
kinase (Figure 1A); furthermore, this nicotine effect is exerted at
the transcriptional level (Figure 1B). The kinetics of mRNA
expression elicited by nicotine mimic those previously reported for
LPS in human monocytes, blood leukocytes, or mice macrophag-
es, in which maximum expression is reached after 3–6 h of
stimulation [22,23,40].
It is worth noting that the IRAK-M up-regulation induced by
nicotine in MØ also occurs in macrophages from a different
species, the mouse (Figure 1C–D). In fact, no significant differ-
ences in relation to the threshold concentration of nicotine or its
Figure 1. Nicotine induces IRAK-M expression in human and mouse macrophages. (A) Western blot analysis of IRAK-M levels in human
macrophages (MØ) stimulated with nicotine or LPS (24 h). (B) Time-course for qPCR analysis of IRAK-M gene expression in nicotine-stimulated MØ;
the square at the right shows the effect of LPS (100 ng.ml21, 6 h); data represent mean 6 SEM of the number of times that mRNA expression is
increased by the stimulus as compared to non-stimulated cells from the same culture (n = 5 different cultures). (C, D) Analysis of IRAK-M protein levels
in MØ and mouse macrophages (RAW 264.7) exposed to increasing concentrations of nicotine (24 h) or incubated with 1 mM nicotine for the
indicated periods. The bars at the bottom of panels A, C and D show pooled results (mean6 SEM) from 5–6 different batches of cells subjected to the
indicated treatment; a typical immunoblot from these experiments is shown in the upper part of these panels. *p#0.05, **p#0.01 and ***p#0.001
comparing stimulated with non-stimulated cells from the same culture (control). {{p#0.01 after comparing the indicated bars.
doi:10.1371/journal.pone.0108397.g001
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Figure 2. The a7 nAChR subtype is involved in the nicotine induction of IRAK-M expression in human macrophages. Expression of a7
nAChRs in human monocytes at different stages of differentiation into MØ was assessed by FACS (A) or confocal microscopy (B, C) using the selective
toxin aBgtx-FITC (3 mg.ml21). FACS analysis shows the expression patterns of aBgtx binding sites in CD14+ cells (black-lined histograms) and in
control cells not-incubated with anti-CD14+ or aBgtx-FITC at the same day of culture (cells alone, gray-shaded histograms); results were reproduced in
4 independent experiments. Typical confocal images from the same culture (n = 4) corresponding to 12-day-old differentiated MØ stained with
aBgtx-FITC with (C) or without (B) pre-incubation with a high concentration of nicotine (500 mM). (D) Transmitted light images of the cells in the same
field as C, and (E) from a different field of the same culture at a higher magnification to reveal the morphological changes of the cells with
differentiation. (F, G) Overexpression of IRAK-M protein induced by nicotine in differentiated MØ is completely abolished by aBgtx and potentiated by
PNU120596; top panels show two typical immunoblots; the bottom panels show pooled results (mean 6 SEM) obtained in 5–7 batches of cells
assayed for each condition. *p#0.05 and ***p#0.001 after comparing nicotine- or LPS-stimulated with non-stimulated cells from the same culture.
{{p#0.01 and {{{p#0.001 after comparison of nicotine-stimulated cells in the presence or absence of aBgtx or PNU120596.
doi:10.1371/journal.pone.0108397.g002
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time-course for stimulating IRAK-M expression were found
between macrophages from either species. Furthermore, the
time-course of the nicotine effect on protein expression in the
two types of macrophage (Figure 1D) is very similar to that
obtained in murine macrophages using adiponectin or LPS as
stimuli [54]. Taken together, the above results indicate that
Figure 3. Pharmacological interference of signaling pathways that could connect a7 nAChRs with IRAK-M in human macrophages.
The effects of selective inhibitors of different kinases [PD98059 (MEK1), U0126 (ERK1/2), SB203580 (p38MAPK), AG-490 (JAK2) and LY 294002 (PI3K)] and
transcription factors [Tanshinone II-A (AP-1) and STA-21 (STAT3)] on nicotine-induced IRAK-M expression (A, B) or on nicotine-mediated
phosphorylation of signaling molecules downstream from a7 nAChRs (C–E) were analyzed by Western blot using the appropriate antibodies (see
Methods section). The target signaling molecules downstream from the receptor were selected based on literature data (see References in the
corresponding Results section). The inhibitors, at the indicated concentrations, were added to the cell culture 30 min before and during the nicotine
stimulation (24 hours for IRAK-M expression, and 30 or 60 min for phosphorylation assays). (A, B) The upper part shows two typical immunoblots with
all the inhibitors assayed. The bars show pooled results (mean 6 SEM) from 6–8 batches of cells assayed for each condition. **p#0.01 and ***p#
0.001 after comparing nicotine- or LPS-stimulated with non-stimulated cells from the same culture. ## p#0.01 and ###p#0.001 after comparing the
effect of the corresponding inhibitor on the up-regulated IRAK-M expression elicited by nicotine. (C–E) Immunoblots evaluating the activation of
different routes triggered by nicotine in MØ and the effect of blockade of the first kinase in each route (ERK1/2, JAK2 or PI3K) with its respective
selective inhibitor (U0126, AG-490 and LY 294002). PVDF membranes with electrotransfered proteins were probed for phospho-ERK1/2, phospho-
JAK2, phospho-STAT3 and phospho-Akt antibodies, using the corresponding non-phospho antibodies (ERK, JAK2, STAT3 and Akt) as controls. Blots
are representative of three independent experiments.
doi:10.1371/journal.pone.0108397.g003
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induction of IRAK-M by nicotine is a reproducible and
generalized process in macrophages, regardless of the species
tested.
Vagus nerve stimulation, as well as exposure to ACh or nicotine,
inhibits the production of TNF-a, IL-1b, IL-6, IL-8, high-mobility
group box 1 (HMGB1), PGE2 and MIP-1a in LPS-activated
mouse or human macrophages [5,6,9]. Some of these studies have
also revealed that a7 nAChRs are specifically responsible for these
anti-inflammatory effects. However, the a4b2 nAChR subtype
expressed in murine alveolar macrophages has also been
implicated in the nicotine-induced suppression of alveolar
macrophage activation by Legionella pneumophila, a causative
agent for pneumonia [55]. Thus, nicotine treatment of these cells
after infection with L. pneumophila significantly and selectively
down-regulated the production of TNF-a, IL-6 and IL-12;
moreover, this anti-inflammatory effect could be completely
blocked by the non-selective antagonist for nAChRs, d-tubocura-
rine, but not by aBgtx.
The above background suggests that at least two nAChR
subtypes may be involved in the nicotine induction of IRAK-M
expression in macrophages, although our data (Figure 2F–G)
clearly indicate that in MØ only a7 nAChRs are actually involved.
Thus, the blockade of this receptor subtype with the selective
antagonist (aBgtx) completely abolished the nicotine effect on
IRAK-M, while the positive allosteric modulator of a7 nAChRs
[56], PNU120596, caused a large and significant concentration-
dependent potentiation of the nicotine effect. It should be noted
that the MØ used in our experiments (differentiated from
monocytes for 10–12 days) abundantly express a7 nAChRs, as
demonstrated by the FACS results and confocal microscopy
images using aBgtx-FITC for receptor labeling (Figure 2A–B).
Although a7 nAChRs may interact with more than 50 different
proteins to trigger multiple intracellular signals [16,17,31,45–
53,57], our results obtained with selective inhibitors for different
signaling molecules (Figure 3A–B) limit the number of possible
pathways involved in the nicotine-mediated effect on IRAK-M
expression to two kinases (JAK2 and PI3K) and one transcription
factor (STAT3). This finding agrees with published observations
[16,31,52] showing that these three components in the down-
stream signaling pathway from a7 nAChR are involved in most of
the pathophysiological responses associated to this receptor
subtype. Our study also shows that pharmacologically interfering
in the MAPK pathway at different levels leaves the nicotine effect
on IRAK-M unaltered (Figure 3A), except for p38MAPK inhibition
using SB203580, which partially and significantly blocks the
IRAK-M up-regulation induced by nicotine. The contribution of
p38MAPK to the nicotine effect may be the result of the ability of
this member of the MAPK family to act at the post-transcriptional
level by regulating mRNA stability and protein translation of
IRAK-M, as has previously been reported with other cytokines,
transcription factors and cell surface receptors [58]. Alternatively,
there could be an autocrine/paracrine loop between p38MAPK and
STAT3 [59] that would also contribute to the IRAK-M
overexpression elicited by nicotine. Further experiments are
needed to explore both proposals.
The finding that the three signaling molecules (JAK2, STAT3
and PI3K/Akt) contribute equally to nicotine-induced IRAK-M
expression (Figure 3B) indicates that these molecules can be
chained to each other or converge on a common signaling
pathway leading to induction of IRAK-M. There are two main
possible signaling cascades for connecting JAK2, STAT3 and
PI3K, and our phosphorylation data using the specific inhibitor of
the first signaling molecule in the cascade confirm that both are
feasible (Figure 3D–E). Through the first cascade, nicotine
stimulation of a7 nAChR directly activates JAK2, which in turn
could phosphorylate both PI3K and STAT3, as has already been
demonstrated conclusively in previous studies [16,52] and is also
supported by our results in MØ (Figure 3D); both activated signals
would eventually, and independently, results in increased IRAK-
M expression. In fact, it has been reported that PI3K activation by
stimuli other than nicotine, such as adiponectin or LPS, result in
IRAK-M overexpression in macrophages [29,54,60,61]. Although
there is no experimental evidence for the transcriptional activation
of the IRAK-M gene by STAT3, it is worth mentioning that the
ChIP analysis done by the ENCODE project [62] using the
lymphoblastic cell line GM12878 shows STAT3 binding sites
within the first intron of the IRAK-M gene to be coincident with
DNase I hypersensitive clusters and histone H3K27ac marks,
features related to active regulatory elements. Indeed, STAT3
activates the transcription of other negative inflammatory regula-
Figure 4. Knockdown of IRAK-M suppressed the anti-inflam-
matory effect of nicotine in LPS-stimulated human macro-
phages. (A) Typical immunoblot showing the knockdown of IRAK-M
expression induced by LPS (100 ng.ml21; 18 h) in MØ transfected with
two non-overlapping siRNA duplexes (siRNA-1 and siRNA-2) specific to
the IRAK-M gene, but not in cells transfected with the negative siRNA
control. (B) ELISA assay of the anti-inflammatory effect of nicotine on
TNF-a production in LPS-stimulated MØ as a function of the silencing of
IRAK-M gene expression. The bars show pooled results (mean 6 SEM)
from 5 batches of cells assayed for each condition. **p#0.01 after
comparing the cytokine production in LPS-stimulated MØ from the
same culture in the absence or presence of nicotine. {{p#0.01 and
{{{p#0.001 after comparing the reversal of the anti-inflammatory effect
of nicotine as a function of the experimental condition being tested. As
expected, the reversal was complete after pre-incubation with aBgtx.
doi:10.1371/journal.pone.0108397.g004
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Figure 5. Nicotinic pretreatment of human macrophages raises IRAK-M expression and reduces TNF-a response to LPS, as in
endotoxin tolerance. (A) Scheme of the experimental design used to test whether nicotine pretreatment can, like LPS, induce a refractory state in
MØ, leading to a reduced inflammatory response to subsequent LPS challenge. (B) Typical immunoblot showing the IRAK-M expression in three
groups of LPS-stimulated MØ preincubated with culture medium, LPS or nicotine; a fourth group of cells from the same batch maintained in culture
medium throughout the experiment (48 h) was used as control (white bar). (C) ELISA analysis of TNF-a levels in MØ supernants from the four groups
listed in B. The bars show pooled results (mean 6 SEM) of 5 different cultures assayed for each condition. **p#0.01 and ***p#0.001 after comparing
any of the three groups of LPS-stimulated MØ with non-stimulated cells from the same culture (control group). {p#0.05, {{p#0.01 and {{{p#0.001
after comparing the indicated bars with LPS-stimulated MØ preincubated with culture medium.
doi:10.1371/journal.pone.0108397.g005
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tors, like SOCS-3, in response to a7 nAChR activation in mice
peritoneal macrophages [16]. The second cascade would be a
signaling pathway through PI3K, activated or not by JAK2, which
could phosphorylate STAT3 via other non-receptor tyrosine
kinases like BMX [63]. In fact, this new alliance between PI3K
and STAT3 has recently been reported in rat nodose ganglion
neurons [64] and in some human cancer cell lines [63]. Our data
in Figure 3E indicated that this alliance also occurs in MØ
stimulated with nicotine.
Once it had been established that nicotine induced overexpres-
sion of IRAK-M via a7 nAChRs in MØ, we next explored the
biological relevance such an up-regulation could have in the anti-
inflammatory effect of nicotine. Our results substantiate its
importance, as can be deduced from the failure of nicotine to
dampen the LPS-induced pro-inflammatory response (TNF-a) in
MØ transfected with specific siRNAs for the IRAK-M gene but
not in cells transfected with the negative siRNA control
(Figure 4B). Selective knock-down of IRAK-M expression in
siRNA-1/22 transfected cultures was clearly evident in the
Western blots, as opposed to the lack of effect on the expression
in cells transfected with a negative siRNA control (Figure 4A).
When immune cells are first subjected to LPS exposure or
undergo TLR activation following an infection: 1) they activate a
rapid inflammatory response (increasing the production of TNF-a
and other inflammatory mediators); and then, 2) they reprogram
their activity and become refractory to further LPS challenge
through the influence of various molecular determinants, like
IRAK-M overexpression [23,36–38]. This refractory state implies
that, when these tolerant cells again come in contact with a
subsequent LPS stimulus, they respond with a reduced TNF-a
production and an increased IRAK-M expression compared to
those generated during prior exposure to LPS. Given the above
scenario, we found that nicotine exposure, through a mechanism
that is similar to that produced by LPS, also leads MØ toward a
tolerant state regarding further LPS challenges (Figure 5B–C).
Thus, following preincubation with nicotine, LPS-activated MØ
show enhanced IRAK-M induction and a reduced pro-inflamma-
tory response (lower TNF-a levels) in relation to LPS-activated
cells not subjected to prior nicotine exposure. This hyporesponsive
state of the immune response in addition to the sustained anti-
inflammatory effect secondary to IRAK-M overexpression elicited
by nicotine, would help explain the known beneficial or negative
effects of smoking in different clinical scenarios [29]. Thus,
smoking is beneficial in ulcerative colitis, a characteristic
inflammatory bowel disorder in which the vast majority of
patients (90%) are non-smokers, while in those with established
disease, smoking results in a less severe course and a lower
likelihood of requiring colectomy [65–67]. Also, induction of
IRAK-M in smokers may be beneficial to the host in early sepsis
by limiting its progression to septic shock and subsequent organ
failure [25,34]. In contrast, there are other settings in which
overexpression of IRAK-M might prevent appropriate host
defense against infection; this could partially explain why smokers
are several times more susceptible to community-acquired
pneumonia or to periodontal tissue infection than nonsmokers
[68–70].
In summary, the findings of our study reveal that induction of
IRAK-M in human macrophages is an intracellular regulator
operating as an effector of the anti-inflammatory action of nicotine
downstream from a7 nAChRs. Furthermore, we also found that
nicotine generates a hyporesponsive state to subsequent challenge
in macrophages. Since both nicotine effects could eventually limit
inappropriate immune activation, or, conversely, compromise the
normal immune response, they should be taken into account in
smokers experiencing different pathologies in which IRAK-M
overexpression may be influential [29].
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